Vaccination as a therapeutic approach to Alzheimer's disease.

Alzheimer's disease is the most common cause of dementia worldwide. Alzheimer's disease is a member of a broad range of neurodegenerative diseases characterized pathologically by the conformational change of a normal protein into a pathological conformer with a high beta-sheet content that renders it neurotoxic. In the case of Alzheimer's disease, the normal soluble amyloid beta peptide is converted into oligomeric/fibrillar amyloid beta. The oligomeric forms of amyloid beta have been hypothesized to be the most toxic, whereas fibrillar amyloid beta becomes deposited as amyloid plaques and congophilic angiopathy, which both serve as neuropathological markers of the disease. In addition, the accumulation of abnormally phosphorylated tau as soluble toxic oligomers and as neurofibrillary tangles is a critical part of the pathology. Numerous therapeutic interventions are under investigation to prevent and treat Alzheimer's disease. Among the most exciting and advanced of these approaches is vaccination. Immunomodulation is being tried for a range of neurodegenerative disorders, with great success being reported in most model animal trials; however, the much more limited human data have shown more modest clinical success so far, with encephalitis occurring in a minority of patients treated with active immunization. The immunomodulatory approaches for neurodegenerative diseases involve targeting a self-protein, albeit in an abnormal conformation; hence, effective enhanced clearance of the disease-associated conformer has to be balanced with the potential risk of stimulating excessive toxic inflammation within the central nervous system. The design of future immunomodulatory approaches that are more focused is dependent on addressing a number of questions, including when is the best time to start immunization, what are the most appropriate targets for vaccination, and is amyloid central to the pathogenesis of Alzheimer's disease or is it critical to target tau-related pathology also. In this review, we discuss the past experience with vaccination for Alzheimer's disease and the development of possible future strategies that target both amyloid beta-related and tau-related pathologies.

[1]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[2]  W. Klein,et al.  Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. , 2009, CNS & neurological disorders drug targets.

[3]  C. Almeida,et al.  Internalized Antibodies to the Aβ Domain of APP Reduce Neuronal Aβ and Protect against Synaptic Alterations*♦ , 2007, Journal of Biological Chemistry.

[4]  R. Nitsch,et al.  Oligodendroglial tau filament formation in transgenic mice expressing G272V tau , 2001, The European journal of neuroscience.

[5]  M. Goedert,et al.  Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. , 1995, The EMBO journal.

[6]  W. H. Jordan,et al.  Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β , 2005, The Journal of Neuroscience.

[7]  G. Bitan,et al.  Dendrimeric Aβ1–15 is an effective immunogen in wildtype and APP-tg mice , 2007, Neurobiology of Aging.

[8]  J. Lucas,et al.  FTDP-17 Mutations in tau Transgenic Mice Provoke Lysosomal Abnormalities and Tau Filaments in Forebrain , 2001, Molecular and Cellular Neuroscience.

[9]  P. Aisen,et al.  Recent developments in Alzheimer's disease therapeutics , 2009, BMC medicine.

[10]  E. Mandelkow,et al.  Abnormal Alzheimer‐like phosphorylation of tau‐protein by cyclin‐dependent kinases cdk2 and cdk5 , 1993, FEBS letters.

[11]  E. Bigio,et al.  Monoclonal antibodies that target pathological assemblies of Aβ , 2007, Journal of neurochemistry.

[12]  A. Delacourte,et al.  Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases , 1997, FEBS letters.

[13]  D. Walsh,et al.  Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host , 2006, Science.

[14]  Rachel L. Mistur,et al.  FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  C. Lemere,et al.  Short Amyloid-β (Aβ) Immunogens Reduce Cerebral Aβ Load and Learning Deficits in an Alzheimer's Disease Mouse Model in the Absence of an Aβ-Specific Cellular Immune Response , 2006, The Journal of Neuroscience.

[16]  A. Delacourte,et al.  Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. , 2007, Archives of neurology.

[17]  P. Hof,et al.  Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms , 2005, The Journal of Neuroscience.

[18]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[19]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[20]  A. Delacourte,et al.  Biochemistry of Tau in Alzheimer’s disease and related neurological disorders , 2008, Expert review of proteomics.

[21]  D. Selkoe,et al.  Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. , 2004, The American journal of pathology.

[22]  R. Black,et al.  Progress in the Active Immunotherapeutic Approach to Alzheimer’s Disease: Clinical Investigations into AN1792-Associated Meningoencephalitis , 2008, Neurodegenerative Diseases.

[23]  Scott A. Small,et al.  Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.

[24]  Thomas Wisniewski,et al.  Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's‐disease‐model transgenic mice shown as by micromagnetic resonance imaging , 2008, Journal of neuroscience research.

[25]  Ling Li,et al.  Role of toll-like receptor signalling in Abeta uptake and clearance. , 2006, Brain : a journal of neurology.

[26]  E. Masliah,et al.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.

[27]  S. Trouche,et al.  Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives. , 2009, Vaccine.

[28]  D. Selkoe,et al.  Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. , 2001, DNA and cell biology.

[29]  V. Blanchard,et al.  Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1 , 2002, Neuroscience Letters.

[30]  Jada Lewis.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein , 2000, Nature Genetics.

[31]  N. Zilka,et al.  Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies , 2009, Acta Neuropathologica.

[32]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[33]  T. Wisniewski,et al.  Disease modifying approaches for Alzheimer's pathology. , 2007, Current pharmaceutical design.

[34]  D. Holtzman,et al.  Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta). , 2004, Alzheimer disease and associated disorders.

[35]  A. Palmeri,et al.  Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus , 2008, The Journal of Neuroscience.

[36]  K. Jellinger,et al.  Alzheimer disease and cerebrovascular pathology: an update , 2002, Journal of Neural Transmission.

[37]  R. Kayed,et al.  Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. , 2009, Current opinion in immunology.

[38]  L. Buée,et al.  P1–062: Alzheimer's disease–like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits , 2006, The American journal of pathology.

[39]  D. Wilcock,et al.  Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage , 2004, Journal of Neuroinflammation.

[40]  J. Trojanowski,et al.  Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. , 2006, The Journal of biological chemistry.

[41]  C. Lemere,et al.  Intranasal immunotherapy for the treatment of Alzheimer’s disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants , 2002, Neurobiology of Aging.

[42]  J. Trojanowski,et al.  Transgenic Mouse Model of Tauopathies with Glial Pathology and Nervous System Degeneration , 2002, Neuron.

[43]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[44]  F. van Leuven,et al.  Changed Conformation of Mutant Tau-P301L Underlies the Moribund Tauopathy, Absent in Progressive, Nonlethal Axonopathy of Tau-4R/2N Transgenic Mice* , 2005, Journal of Biological Chemistry.

[45]  Naoaki Saito,et al.  Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation , 2005, FEBS letters.

[46]  D. Selkoe,et al.  Nasal Vaccination with β-Amyloid Peptide for the Treatment of Alzheimer's Disease , 2001 .

[47]  Ayodeji A. Asuni,et al.  Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements , 2007, The Journal of Neuroscience.

[48]  D. Peabody,et al.  Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. , 2006, Vaccine.

[49]  M. Staufenbiel,et al.  Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy , 2002, Science.

[50]  M. Kirschner,et al.  Tau protein binds to microtubules through a flexible array of distributed weak sites , 1991, The Journal of cell biology.

[51]  T. Wisniewski,et al.  Induction of Toll-Like Receptor 9 Signaling as a Method for Ameliorating Alzheimer's Disease-Related Pathology , 2009, The Journal of Neuroscience.

[52]  D. Selkoe,et al.  Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation , 1996, Neurobiology of Disease.

[53]  K. Henke,et al.  Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.

[54]  R. Nitsch,et al.  In Vivo Analysis of Wild‐type and FTDP‐17 Tau Transgenic Mice , 2000, Annals of the New York Academy of Sciences.

[55]  Jun Tan,et al.  Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology , 2008, Nature Medicine.

[56]  E. Sigurdsson.  Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. , 2009, Current Alzheimer research.

[57]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[58]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[59]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[60]  J. Brion,et al.  Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. , 1999, The American journal of pathology.

[61]  T. Wisniewski,et al.  Immunotherapy targeting abnormal protein conformation , 2009, Alzheimer's & Dementia.

[62]  J. Walker,et al.  Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[63]  V. Vasilevko,et al.  Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice , 2008, Journal of Neuroinflammation.

[64]  J. Trojanowski,et al.  Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. , 2001, The American journal of pathology.

[65]  Fei Liu,et al.  Microtubule-associated protein tau in development, degeneration and protection of neurons , 2008, Progress in Neurobiology.

[66]  Yun Bai,et al.  Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[67]  C. Rowe,et al.  Imaging β-amyloid burden in aging and dementia , 2007, Neurology.

[68]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Hirotaka Yoshida,et al.  Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein , 2002, The Journal of Neuroscience.

[70]  Elizabeth Head,et al.  The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. , 2008, Journal of Alzheimer's disease : JAD.

[71]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[72]  Thomas Wisniewski,et al.  A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice , 2008, Neurobiology of Aging.

[73]  A. Delacourte,et al.  Mitotic-like Tau Phosphorylation by p25-Cdk5 Kinase Complex* , 2003, Journal of Biological Chemistry.

[74]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[75]  E. Sigurdsson,et al.  Therapeutic approaches for prion and Alzheimer's diseases , 2007, The FEBS journal.

[76]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[77]  J. Brion,et al.  ALZHEIMER'S DISEASE AND TAU PROTEINS , 1986, The Lancet.

[78]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[79]  A. Delacourte,et al.  Absence of β-amyloid deposits after immunization in Alzheimer disease with lewy body dementia , 2007 .

[80]  L. Edmonds,et al.  CONGENITAL MALFORMATIONS AND VINYL CHLORIDE , 1975, The Lancet.

[81]  Akihiko Takashima,et al.  Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice , 2005, Brain Research.

[82]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[83]  W. Noble,et al.  Molecular motors implicated in the axonal transport of tau and alpha-synuclein. , 2005, Journal of cell science.

[84]  F. LaFerla,et al.  Pathways by which Abeta facilitates tau pathology. , 2006, Current Alzheimer research.

[85]  Yun Bai,et al.  Transcutaneous β-amyloid immunization reduces cerebral β-amyloid deposits without T cell infiltration and microhemorrhage , 2007, Proceedings of the National Academy of Sciences.

[86]  T. Hashikawa,et al.  Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[87]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[88]  D. Quartermain,et al.  Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages , 2006, The European journal of neuroscience.

[89]  Hyoung-Gon Lee,et al.  Alzheimer Disease Pathology As a Host Response , 2008, Journal of neuropathology and experimental neurology.

[90]  C. Almeida,et al.  Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. , 2007, The Journal of biological chemistry.

[91]  A. Kiyatkin,et al.  Anti-Aβ1–11 Antibody Binds to Different β-Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers* , 2007, Journal of Biological Chemistry.

[92]  K. Titani,et al.  Hyperphosphorylation of Tau in PHF , 1995, Neurobiology of Aging.

[93]  M. Pool,et al.  Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. , 2001 .

[94]  I. Ferrer,et al.  A&bgr; Species Removal After A&bgr;42 Immunization , 2006, Journal of neuropathology and experimental neurology.

[95]  T. Town,et al.  CD40L disruption enhances Aβ vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation , 2008, Neurobiology of Disease.

[96]  John Q Trojanowski,et al.  Transgenic animal models of tauopathies. , 2005, Biochimica et biophysica acta.

[97]  T. Kokjohn,et al.  Of mice and men: The relevance of transgenic mice Aβ immunizations to Alzheimer's disease , 2002 .

[98]  B. Solomon.  Antibody-mediated immunotherapy for Alzheimer's disease. , 2007, Current opinion in investigational drugs.

[99]  D. Holtzman,et al.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[100]  V. Vasilevko,et al.  Prototype Alzheimer’s Disease Vaccine Using the Immunodominant B Cell Epitope from β-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide1 , 2005, The Journal of Immunology.

[101]  M. Frosch,et al.  The cerebral beta-amyloid angiopathies: hereditary and sporadic. , 2006, Brain pathology.

[102]  R. Nitsch,et al.  Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease , 2002, Nature Medicine.

[103]  T. Wisniewski,et al.  Immunological and Anti‐Chaperone Therapeutic Approaches for Alzheimer Disease , 2005, Brain pathology.

[104]  A. Kiyatkin,et al.  Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. , 2007, The Journal of biological chemistry.

[105]  R. A. Crowther,et al.  Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein , 2000, Acta Neuropathologica.

[106]  Frank R. Ervin,et al.  Alzheimer's Disease Aβ Vaccine Reduces Central Nervous System Aβ Levels in a Non-Human Primate, the Caribbean Vervet , 2004 .

[107]  F. Heppner,et al.  Cerebral and Peripheral Amyloid Phagocytes— an Old Liaison with a New Twist , 2008, Neuron.

[108]  D. Holtzman,et al.  Active and passive immunotherapy for neurodegenerative disorders. , 2008, Annual review of neuroscience.

[109]  Patrick R. Hof,et al.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.

[110]  D. Wilcock,et al.  Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. , 2007, Neuroscience.

[111]  A. Erisir,et al.  Tau-dependent microtubule disassembly initiated by prefibrillar β-amyloid , 2006, The Journal of cell biology.

[112]  L. Jenkins,et al.  Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD , 2005, Neurology.

[113]  I. Ferrer,et al.  Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease , 2004, Brain pathology.

[114]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[115]  C. Geula,et al.  Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease , 2007, Nature Medicine.

[116]  R. A. Crowther,et al.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease , 1989, Neuron.

[117]  J. Götz,et al.  Animal models of Alzheimer's disease and frontotemporal dementia , 2008, Nature Reviews Neuroscience.

[118]  T. Wisniewski,et al.  Amyloid-β immunisation for Alzheimer's disease , 2008, The Lancet Neurology.

[119]  R. Nitsch,et al.  Tau Filament Formation in Transgenic Mice Expressing P301L Tau* , 2001, The Journal of Biological Chemistry.

[120]  B. Jenkins,et al.  Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice , 2008, Brain Research.

[121]  Michal Schwartz,et al.  Selective ablation of bone marrow‐derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model , 2007, The European journal of neuroscience.

[122]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[123]  Martin F. Bachmann,et al.  The coming of age of virus-like particle vaccines , 2008, Biological chemistry.

[124]  W. K. Cullen,et al.  A β dimer-containing human cerebrospinal fluid disrupts synaptic plasticity : prevention by systemic passive immunization , 2009 .

[125]  T. Wisniewski.  Is amyloid-β-peptide immunization clinically effective in patients with Alzheimer's disease? , 2005, Nature Clinical Practice Neurology.

[126]  Z. Kouchi,et al.  FAD mutants unable to increase neurotoxic Aβ 42 suggest that mutation effects on neurodegeneration may be independent of effects on Aβ , 2006, Journal of neurochemistry.

[127]  John Hardy,et al.  A Hundred Years of Alzheimer's Disease Research , 2006, Neuron.

[128]  R. Kopito,et al.  Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates , 2009, Nature Cell Biology.

[129]  J. Trojanowski,et al.  Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice* , 2006, Journal of Biological Chemistry.

[130]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[131]  B. Solomon,et al.  Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .

[132]  E. Masliah,et al.  Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease , 2005, Neurology.

[133]  D. Borchelt,et al.  Papillomavirus-Like Particles Are an Effective Platform for Amyloid-β Immunization in Rabbits and Transgenic Mice1 , 2006, The Journal of Immunology.

[134]  M. Hill,et al.  A Two-Year Study with Fibrillar β-Amyloid (Aβ) Immunization in Aged Canines: Effects on Cognitive Function and Brain Aβ , 2008, The Journal of Neuroscience.

[135]  P. S. St George-Hyslop,et al.  Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation. , 2006, The American journal of pathology.

[136]  T. Fath,et al.  Tau-Mediated Cytotoxicity in a Pseudohyperphosphorylation Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[137]  E. Head,et al.  Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine — A Novel Immunotherapeutic Strategy , 2008, PloS one.

[138]  D. Holtzman,et al.  Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. , 2009, CNS & neurological disorders drug targets.

[139]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[140]  B Frangione,et al.  Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. , 2001, The American journal of pathology.

[141]  M. Fonseca,et al.  The double-edged flower: roles of complement protein C1q in neurodegenerative diseases. , 2006, Advances in experimental medicine and biology.

[142]  C. Lemere,et al.  Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. , 2006, Rejuvenation research.

[143]  Bin Zhang,et al.  Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform , 1999, Neuron.

[144]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[145]  Akihiko Takashima,et al.  Formation of Filamentous Tau Aggregations in Transgenic Mice Expressing V337M Human Tau , 2001, Neurobiology of Disease.

[146]  W. K. Cullen,et al.  Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization , 2008, The Journal of Neuroscience.

[147]  D. Holtzman,et al.  Alzheimer’s Aβ vaccination of rhesus monkeys (Macaca mulatta) , 2004, Mechanisms of Ageing and Development.

[148]  E. Head,et al.  Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle. , 2009, CNS & neurological disorders drug targets.

[149]  D. Boche,et al.  The role of the immune system in clearance of Abeta from the brain. , 2008, Brain pathology.

[150]  C. Glabe,et al.  Structural Classification of Toxic Amyloid Oligomers* , 2008, Journal of Biological Chemistry.

[151]  M. Frosch,et al.  The Cerebral β‐Amyloid Angiopathies: Hereditary and Sporadic , 2006 .

[152]  C. Cotman,et al.  Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. , 2003, International immunology.

[153]  A. Aguzzi.  Cell biology: Beyond the prion principle , 2009, Nature.

[154]  N. Relkin,et al.  18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease , 2009, Neurobiology of Aging.

[155]  D. Quartermain,et al.  An Attenuated Immune Response Is Sufficient to Enhance Cognition in an Alzheimer's Disease Mouse Model Immunized with Amyloid-β Derivatives , 2004, The Journal of Neuroscience.

[156]  E. Sigurdsson,et al.  Immunization for Alzheimer's disease , 2002 .

[157]  J. Brion,et al.  Expression of tau mRNA and soluble tau isoforms in affected and non‐affected brain areas in Alzheimer's disease , 2004, FEBS letters.

[158]  E. Sigurdsson.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. , 2008, Journal of Alzheimer's disease : JAD.

[159]  R. Ferrante,et al.  Conformation-sensitive Antibodies against Alzheimer Amyloid-β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide* , 2007, Journal of Biological Chemistry.

[160]  W. Noble,et al.  Molecular motors implicated in the axonal transport of tau and α-synuclein , 2005, Journal of Cell Science.

[161]  Khadija Iqbal,et al.  Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce β-amyloid fibrils , 2004, Acta Neuropathologica.

[162]  Leonard Petrucelli,et al.  The role of tau in neurodegeneration , 2009, Molecular Neurodegeneration.

[163]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[164]  F. Nicoletti,et al.  β-Amyloid Monomers Are Neuroprotective , 2009, The Journal of Neuroscience.

[165]  W. Klein,et al.  Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.

[166]  W. Noble,et al.  Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfolding , 2009, Prion.

[167]  W. Klein,et al.  Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. , 2006, The Journal of biological chemistry.

[168]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[169]  M. Goedert,et al.  Interaction of tau protein with the dynactin complex , 2007, The EMBO journal.

[170]  H. Geerts,et al.  Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. , 1999, The American journal of pathology.

[171]  P. Davies,et al.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms , 2003, Journal of neurochemistry.

[172]  J. Brion,et al.  Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1 , 2004, Neurobiology of Disease.

[173]  J. Brion.  Immunological demonstration of tau protein in neurofibrillary tangles of Alzheimer's disease , 2006 .

[174]  D. Boche,et al.  SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer' Disease: The Role of the Immune System in Clearance of Aβ from the Brain , 2008 .

[175]  E. Sigurdsson,et al.  High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice , 2008, Neuroscience.